Abstract: There is provided a thrombin inhibitor polypeptide and DNA(RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. The anti-thrombin polypeptide is used to treat various diseases where prevention of blood clotting is necessary and is of therapeutic value. The present invention also discloses a method of producing the anti-thrombin polypeptide and methods for its use as a pharmaceutical composition.

Abstract: Drug which contains human growth hormones capable of recovering the renal function when administered to a patient who has renal insufficiency but has not yet undergone kidney dialysis. By administrating the drug, the loss of renal function represented by an extreme decrease in creatinine clearance or the reciprocal of blood creatinine level can be prevented and thus it can dispense with the dialytic treatment for patients with renal insufficiency.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Abstract: Human growth hormone variants and their nucleic acids are disclosed wherein the amino acid residues at positions 10, 14, 18, 21, 167, 171, 174, 176 and 179 have been replaced with other amino acids. Also claimed are vectors and host cells comprising these human growth hormone variants as well as processes for their preparation.

Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.

Abstract: Disclosed herein are a modified epimorphin obtained by adding a hydrophilic peptide composed of 5 to 99 amino acids to at least one terminus of a polypeptide containing the functional domain of epimorphin, and a modified epimorphin composed of a polypeptide having a structure wherein a hydrophobic domain adjacent to the C-terminus of the whole-length epimorphin consisting of a coiled coil domain (1) on the N-terminal side, a functional domain (2) at the center, a coiled coil domain (3) on the C-terminal side and the hydrophobic domain (4) adjacent to the C-terminus has been deleted from the whole-length epimorphin, and at least part of amino acids have been deleted from the terminal side of at least one of the coiled coil domains (1) and (3) as well.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Abstract: The present invention provides compositions for stimulating an increase in islet proliferation and .beta.-cell mass using an insulin homolog polypeptide. The present invention also includes methods for treating diabetes by stimulating islet proliferation and .beta.-cell mass increases and affecting insulin levels.

Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Abstract: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.

Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as "KGF-2" also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

Abstract: A method is disclosed which provides for the proliferation and growth of cells, such as prostate cells, by contacting them with an effective amount of a placental-derived prostate growth factor.

Abstract: The present invention provides PR domain peptides, which are about 100 to about 120 amino acids in length and contain three highly conserved sequences of about 10 to about 12 amino acids, separated by less conserved sequences of about 20 to about 35 amino acids.

Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.

Abstract: The present invention relates to a novel CLC protein which is a member of the IL-6 cytokine family. In particular, isolated nucleic acid molecules are provided encoding the human CLC protein. CLC polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CLC activity. Also provided are diagnostic methods for detecting cardiac and immune system-related disorders and therapeutic methods for treating cardiac and immune system-related disorders.

Abstract: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeuticall sefl fragments, analogs, or derivatives thereof, and DNA (RNA) enco such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

Abstract: A human cDNA encoding human myotrophin and the polypeptide encoded thereby and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing the human myotrophin polynucleotides and polypeptides encoded thereby for the treatment of diseases relating to cellular hypertrophy, among others. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.

Abstract: Methods are provided to regulate the trafficking of nuclear proteins, including the high molecular weight forms of FGF-2, to the nucleus. A nuclear trafficking component, which is approximately 29 kD, is identified as binding to and regulating nuclear localization of FGF-2. Inhibitors of the binding of the 29 kD component and FGF-2 are provided.

Abstract: A diagnostic method is described for the detection of placental-derived growth factors which involves contacting a biological tissue or fluid sample with a labeled antibody which is specific to the growth factors and detecting the labeled reaction product.

Abstract: Growth hormone participates in the regulation of normal growth and development processes. The binding affinity of growth hormone for its target receptors is dependent upon the interaction of site 1 and site 2 domains of growth hormone with the target receptor. Embodiments of the present invention include site 1 variants of human growth hormone which bind to target receptors with a different affinity than that of the native hormone. Embodiments of the invention further include components for the production of isolated human growth hormone variants using a host cell/vector expression system.